GENE ONLINE|News &
VERVE-102 Phase Ib Trial Shows LDL-C Reduction, Different Safety Profile Than VERVE-101
A Phase Ib trial of VERVE-102 demonstrated a reduction in low-density lipoprotein cholesterol (LDL-C) levels. The trial reported no serious safety concerns. The results contrast with those from Verve Therapeutics’ VERVE-101 program. The VERVE-102 trial is currently in Phase Ib, which is designed to assess safety and determine effective dosage. The company reported that VERVE-102 appears to have a different safety profile than the company’s VERVE-101 programme.
Newsflash | Powered by GeneOnline AI
Date: April 14, 2025
Related posts:
FDA Granted Accelerated Approval to Vitrakvi (Larotrectinib) in November 2018
State Attorneys General Investigate PBM Influence Over Health Plans Amid Concerns of Self-Benefit
Securing Biologic Drug Patents: Article Explores Strategies for a Market Representing Over 40% of Global Pharmaceutical Sales.
Top 5 Generic Drug Makers Control 70% of Market: Blog Post Outlines Strategies for New Entrants
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
